Cantor Fitzgerald Reiterates Overweight on Intra-Cellular Therapies, Maintains $101 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating on Intra-Cellular Therapies (NASDAQ:ITCI) and maintained a $101 price target.
February 23, 2024 | 5:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald reaffirmed an Overweight rating on Intra-Cellular Therapies with a $101 price target.
The reiteration of an Overweight rating and maintenance of a high price target by a reputable analyst like Charles Duncan from Cantor Fitzgerald could instill confidence among investors and potentially drive the stock price up in the short term. The specific mention of a $101 price target suggests a strong bullish outlook on the stock, which could influence investor sentiment positively.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100